Current and Future Therapies for Advanced Gastric Cancer

Clinical Colorectal Cancer

Volumn 14, Issue 4, 2015, Pages 239-250

  Davidson, Michael ^a   Okines, Alicia F C ^a   Starling, Naureen ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Advanced gastric cancer; Chemotherapy; Immunotherapy; Molecular stratification; Targeted agents

Indexed keywords

CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EVEROLIMUS; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IMMUNOMODULATING AGENT; IRINOTECAN; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PEMBROLIZUMAB; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAMUCIRUMAB; RILOTUMUMAB; SCATTER FACTOR RECEPTOR; SORAFENIB; SUNITINIB; TRASTUZUMAB; TREBANANIB; UNINDEXED DRUG; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER THERAPY; HUMAN; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; STOMACH CANCER; SURVIVAL TIME; DRUG DESIGN; IMMUNOTHERAPY; PATHOLOGY; PATIENT SELECTION; PROCEDURES; STOMACH NEOPLASMS; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG DESIGN; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; PATIENT SELECTION; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 84947789537     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2015.05.013     Document Type: Review

References (109)

1. Ferlay J, Soerjomataram I, Ervik M, Forman D, Bray F, GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide. IARC CancerBase, accessed 16/12/14. International Agency for Research on Cancer.
2. H.S. Kim, H. Lee, H.C. Jeung, and et al. Advanced detection of recent changing trends in gastric cancer survival: up-to-date comparison by period analysis Jpn J Clin Oncol 41 2011 1344 1350
3. D. Cunningham, W.H. Allum, S.P. Stenning, and et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med 355 2006 11 20
4. S. Sakuramoto, M. Sasako, T. Yamaguchi, and et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine N Engl J Med 357 2007 1810 1820
5. A.D. Wagner, S. Unverzagt, W. Grothe, and et al. Chemotherapy for advanced gastric cancer Cochrane Database Syst Rev 2010 CD004064
6. A.M. Dulak, S.E. Schumacher, J. van Lieshout, and et al. Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis Cancer Res 72 2012 4383 4393
7. N. Deng, L.K. Goh, H. Wang, and et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets Gut 61 2012 673 684
8. Cancer Genome Atlas Research Network Comprehensive molecular characterization of gastric adenocarcinoma Nature 513 2014 202 209
9. A.D. Wagner, W. Grothe, J. Haerting, G. Kleber, A. Grothey, and W.E. Fleig Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data J Clin Oncol 24 2006 2903 2909
10. J. Ajani Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers Cancer 107 2006 221 231
11. N. Boku, S. Yamamoto, H. Fukuda, and et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study Lancet Oncol 10 2009 1063 1069
12. Y.K. Kang, W.K. Kang, D.B. Shin, and et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial Ann Oncol 20 2009 666 673
13. W. Koizumi, H. Narahara, T. Hara, and et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 2008 215 221
14. J.A. Ajani, W. Rodriguez, G. Bodoky, and et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial J Clin Oncol 28 2010 1547 1553
15. S.E. Al-Batran, J.T. Hartmann, S. Probst, and et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie J Clin Oncol 26 2008 1435 1442
16. D. Cunningham, N. Starling, S. Rao, and et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 358 2008 36 46
17. A.F. Okines, A.R. Norman, P. McCloud, Y.K. Kang, and D. Cunningham Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer Ann Oncol 20 2009 1529 1534
18. G. Group, K. Oba, X. Paoletti, and et al. Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis Eur J Cancer 49 2013 1565 1577
19. E. Van Cutsem, V.M. Moiseyenko, S. Tjulandin, and et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group J Clin Oncol 24 2006 4991 4997
20. A.D. Roth, N. Fazio, R. Stupp, and et al. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research J Clin Oncol 25 2007 3217 3223
21. N.C. Tebbutt, M.M. Cummins, T. Sourjina, and et al. Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial Br J Cancer 102 2010 475 481
22. W. Koizumi, Y.H. Kim, M. Fujii, and et al. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START) J Cancer Res Clin Oncol 140 2014 319 328
23. M. Dank, J. Zaluski, C. Barone, and et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction Ann Oncol 19 2008 1450 1457
24. R. Guimbaud, C. Louvet, P. Ries, and et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study J Clin Oncol 32 2014 3520 3526
25. P.C. Thuss-Patience, A. Kretzschmar, D. Bichev, and et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Eur J Cancer 47 2011 2306 2314
26. J.H. Kang, S.I. Lee, H. Lim do, and et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone J Clin Oncol 30 2012 1513 1518
27. H.E. Ford, A. Marshall, J.A. Bridgewater, and et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial Lancet Oncol 15 2014 78 86
28. H.S. Kim, H.J. Kim, S.Y. Kim, and et al. Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis Ann Oncol 24 2013 2850 2854
29. S. Hironaka, S. Ueda, H. Yasui, and et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial J Clin Oncol 31 2013 4438 4444
30. S.J. Sym, J. Hong, J. Park, and et al. A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy Cancer Chemother Pharmacol 71 2013 481 488
31. J.M. Daly, M.A. Olayioye, A.M. Wong, and et al. NDF/heregulin-induced cell cycle changes and apoptosis in breast tumor cells: role of PI3 kinase and p38 MAP kinase pathways Oncogene 18 1999 3440 3451
32. R. Worthylake, L.K. Opresko, and H.S. Wiley ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors J Biol Chem 274 1999 8865 8874
33. S. Fukushige, K. Matsubara, M. Yoshida, and et al. Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line Mol Cell Biol 6 1986 955 958
34. D.J. Slamon, B. Leyland-Jones, S. Shak, and et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792
35. I. Smith, M. Procter, R.D. Gelber, and et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet 369 2007 29 36
36. J.E. Boers, H. Meeuwissen, and N. Methorst HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH) Histopathology 58 2011 383 394
37. Y. Bang, H. Chung, J. Xu, and et al. Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial (abstract 4556) J Clin Oncol 27 15 suppl 2009
38. Y.Y. Janjigian, D. Werner, C. Pauligk, and et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis Ann Oncol 23 2012 2656 2662
39. M. Terashima, K. Kitada, A. Ochiai, and et al. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer Clin Cancer Res 18 2012 5992 6000
40. M. Hofmann, O. Stoss, D. Shi, and et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study Histopathology 52 2008 797 805
41. Y.J. Bang, E. Van Cutsem, A. Feyereislova, and et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 2010 687 697
42. J.R. Hecht, Y.J. Bang, S. Qin, and et al. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): the TRIO-013/LOGiC trial (abstract LBA4001) J Clin Oncol 31 suppl 15 2013
43. T. Satoh, R. Xu, H. Chung, and et al. Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN - A Randomized, Phase III Study J Clin Oncol 32 2014 2039 2049
44. E. Van Cutsem, S. de Haas, Y.K. Kang, and et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial J Clin Oncol 30 2012 2119 2127
45. L. Shen, J. Li, J.M. Xu, and et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized double-blind phase III study (AVATAR study) Gastric Cancer 18 2015 168 176
46. C.S. Fuchs, J. Tomasek, C.J. Yong, and et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial Lancet 383 2014 31 39
47. H. Wilke, K. Muro, E. Van Cutsem, and et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial Lancet Oncol 15 2014 1224 1235
48. S. Qin Phase III study of apatinib in advanced gastric cancer: a randomized, double-blind, placebo-controlled trial (abstract 4003) J Clin Oncol 32 suppl 5 2014
49. T. Waddell, I. Chau, D. Cunningham, and et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial Lancet Oncol 14 2013 481 489
50. F. Lordick, Y.K. Kang, H.C. Chung, and et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial Lancet Oncol 14 2013 490 499
51. S.J. Dutton, D.R. Ferry, J.M. Blazeby, and et al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial Lancet Oncol 15 2014 894 904
52. A. Ohtsu, J.A. Ajani, Y.X. Bai, and et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study J Clin Oncol 31 2013 3935 3943
53. S. Verma, D. Miles, L. Gianni, and et al. Trastuzumab emtansine for HER2-positive advanced breast cancer N Engl J Med 367 2012 1783 1791
54. R. Pinkas-Kramarski, L. Soussan, H. Waterman, and et al. Diversification of neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions Embo J 15 1996 2452 2467
55. J. Baselga, J. Cortes, S.B. Kim, and et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer N Engl J Med 366 2012 109 119
56. C.E. Geyer, J. Forster, D. Lindquist, and et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2006 2733 2743
57. S. Iqbal, B. Goldman, C.M. Fenoglio-Preiser, and et al. Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer Ann Oncol 22 2011 2610 2615
58. Z.A. Wainberg, A. Anghel, A.J. Desai, and et al. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo Clin Cancer Res 16 2010 1509 1519
59. K.L. Blackwell, H.J. Burstein, A.M. Storniolo, and et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer J Clin Oncol 28 2010 1124 1130
60. D.Y. Oh, K.W. Lee, J.Y. Cho, and et al. A phase II open-label trial of dacomitinib monotherapy in patients with HER2-positive advanced gastric cancer after failure of at least one prior chemotherapy regimen (abstract 54) J Clin Oncol 30 suppl 4 2012
61. J. Folkman Tumor angiogenesis: therapeutic implications N Engl J Med 285 1971 1182 1186
62. H. Hurwitz, L. Fehrenbacher, W. Novotny, and et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
63. K. Miller, M. Wang, J. Gralow, and et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2007 2666 2676
64. R.A. Burger, M.F. Brady, M.A. Bookman, and et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer N Engl J Med 365 2011 2473 2483
65. T.J. Perren, A.M. Swart, J. Pfisterer, and et al. A phase 3 trial of bevacizumab in ovarian cancer N Engl J Med 365 2011 2484 2496
66. D. Cunningham, E. Smyth, S. Stenning, and et al. Peri-operative chemotherapy ± bevacizumab for resectable gastro-oesophageal adenocarcinoma: Results from the UK Medical Research Council randomised ST03 trial European Cancer Congress 2015 abstract no. 2201. Available at: https://www.europeancancercongress.org/Scientific-Programme/Abstract-search?abstractid=20318. Accessed: October 15,2015
67. Y.J. Bang, Y.K. Kang, W.K. Kang, and et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer Invest New Drugs 29 2011 1449 1458
68. W. Sun, M. Powell, P.J. O'Dwyer, P. Catalano, R.H. Ansari, and A.B. Benson 3rd Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203 J Clin Oncol 28 2010 2947 2951
69. J. Li, S. Qin, J. Xu, and et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial J Clin Oncol 31 2013 3219 3225
70. INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG)- Final overall and subgroup results (abstr 4003) J Clin Oncol 33 suppl 3 2015
71. E. Van Cutsem, J. Tabernero, R. Lakomy, and et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen J Clin Oncol 30 2012 3499 3506
72. M.M. Eatock, N.C. Tebbutt, C.L. Bampton, and et al. Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer Ann Oncol 24 2013 710 718
73. R.G. Amado, M. Wolf, M. Peeters, and et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 2008 1626 1634
74. C.S. Karapetis, S. Khambata-Ford, D.J. Jonker, and et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 2008 1757 1765
75. J.Y. Douillard, S. Siena, J. Cassidy, and et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study J Clin Oncol 28 2010 4697 4705
76. M. Peeters, T.J. Price, A. Cervantes, and et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer J Clin Oncol 28 2010 4706 4713
77. E. Van Cutsem, C.H. Kohne, E. Hitre, and et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
78. A.F. Sobrero, J. Maurel, L. Fehrenbacher, and et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer J Clin Oncol 26 2008 2311 2319
79. J.Y. Douillard, K.S. Oliner, S. Siena, and et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer N Engl J Med 369 2013 1023 1034
80. M. Moehler, A. Mueller, T. Trarbach, and et al. Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study Ann Oncol 22 2011 1358 1366
81. C. Pinto, F. Di Fabio, S. Siena, and et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study) Ann Oncol 18 2007 510 517
82. T.S. Mok, Y.L. Wu, S. Thongprasert, and et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
83. D.J. Adelstein, C.P. Rodriguez, L.A. Rybicki, and et al. A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastoesophageal junction Invest New Drugs 30 2012 1684 1689
84. R. Petty, A. Dahle-Smith, Z. Miedzybrodzka, and et al. Epidermal growth factor receptor copy number gain (EGFR CNG) and response to gefitinib in esophageal cancer (EC): Results of a biomarker analysis of a phase III trial of gefitinib versus placebo (TRANS-COG) J Clin Onc 32 2014 abstract 4016
85. D.Z. Xu, Q.R. Geng, Y. Tian, and et al. Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer BMC Cancer 10 2010 536
86. G. Yu, J. Wang, Y. Chen, and et al. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer Clin Cancer Res 15 2009 1821 1829
87. T. Doi, K. Muro, N. Boku, and et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer J Clin Oncol 28 2010 1904 1910
88. S.J. Lee, J. Lee, J. Lee, and et al. Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients Invest New Drugs 31 2013 1580 1586
89. C. Zhang, N. Awasthi, M.A. Schwarz, and R.E. Schwarz The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer Int J Oncol 43 2013 1627 1635
90. B. Bhattacharya, M. Akram, I. Balasubramanian, and et al. Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-fluorouracil in PIK3CA mutant gastric cancer cells Cancer Biol Ther 13 2012 34 42
91. E. Oki, H. Baba, E. Tokunaga, and et al. Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer Int J Cancer 117 2005 376 380
92. J.Y. An, K.M. Kim, M.G. Choi, and et al. Prognostic role of p-mTOR expression in cancer tissues and metastatic lymph nodes in pT2b gastric cancer Int J Cancer 126 2010 2904 2913
93. A.F. Okines, D. Gonzalez de Castro, D. Cunningham, and et al. Biomarker analysis in oesophagogastric cancer: results from the REAL3 and TransMAGIC trials Eur J Cancer 49 2013 2116 2125
94. J. Lin, D. Sampath, M.A. Nannini, and et al. Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models Clin Cancer Res 19 2013 1760 1772
95. H.E. Lee, M.A. Kim, H.S. Lee, and et al. MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome Br J Cancer 107 2012 325 333
96. T. Iveson, R.C. Donehower, I. Davidenko, and et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study Lancet Oncol 15 2014 1007 1018
97. E. KWAK, P. LoRusso, O. Hamid, and et al. Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer Journal Clin Oncol 33 2015 abstr 1
98. M. Shah, Y.-J. Bang, F. Lordick, and et al. METGastric: A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC) Journal Clin Oncol 33 2015 abstract 4012
99. D. Cunningham, N. Tebbutt, A. Murad, and et al. Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study Journal Clin Oncol 33 2015 abstract 4000
100. K. Kunii, L. Davis, J. Gorenstein, and et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival Cancer Res 68 2008 2340 2348
101. L. Xie, X. Su, D. Zhang, and et al. AZD4547, a potent and selective inhibitor of FGF-receptor tyrosine kinases 1, 2 and 3, inhibits the growth of FGF-receptor 2 driven gastric cancer models in vitro and in vivo (abstract 1643) Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research 71 suppl 8 2011
102. Randomized A, open-label phase II study of AZD4547 versus Paclitaxel in previously treated patients with advanced gastric cancer (AGC) with Fibroblast Growth Factor Receptor 2 (FGFR2) polysomy or gene amplification: SHINE study (abstr 4014) J Clin Oncol 33 suppl 2015
103. E. Smyth, N. Turner, C. Peckitt, and et al. Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours J Clin Oncol 33 2015 abstract 2508
104. S.B. Kaye, J. Lubinski, U. Matulonis, and et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer J Clin Oncol 30 2012 372 379
105. H.S. Kim, M.A. Kim, D. Hodgson, and et al. Concordance of ATM (ataxia telangiectasia mutated) immunohistochemistry between biopsy or metastatic tumor samples and primary tumors in gastric cancer patients Pathobiology 80 2013 127 137
106. D. Hodgson, H. Mason, L. Oplustilova, and et al. Activity of the PARP inhibitor olaparib in ATM-deficient gastric cancer: From preclinical models to the clinic Proc Am Assoc Cancer Res 2014 2398 (abstr)
107. Bang Y-J, Im S-A, Lee K-W, et al. Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours. J Clin Oncol, published online ahead of print August 2015, Available at: http://jco.ascopubs.org/content/early/2015/08/11/JCO.2014.60.0320. abstract. Accessed: October 15,2015.
108. S. Matsueda, and D.Y. Graham Immunotherapy in gastric cancer World J Gastroenterol 20 2014 1657 1666
109. K. Muro, Y.J. Bang, V. Shankaran, and et al. Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012 (abstract 3) J Clin Oncol 33 suppl 3 2015